Cancer Patients’ Willingness to Pay per Quality-Adjusted Life Year in ASIA-Pacific: A Systematic Review and Correlation Analysis with Population Metrics
Author(s)
GE X1, Zhou A2, Chen J3
1NHS England, London, UK, 2University of York, York, UK, 3Roche Hong Kong and Macau, Kowloon, Hong Kong
Presentation Documents
OBJECTIVES: Cancer patients’ Willingness To Pay per Quality-adjusted life year (Ca-WTPQ) in Asia-Pacific has not been sufficiently studied and reviewed. When direct evidence is unavailable, it is unclear whether GDP per capita or the general population’s WTPQ (Gp-WTPQ) could facilitate the estimation of Ca-WTPQ. This study is timely to synthesize studies on a country/economy level in regards to Ca-WTPQ, and its correlation with population metrics. METHODS: PubMed, EconBiz, CiNii (Japanese) and CNKI (Chinese) bibliographic databases, and Value in Health journal were searched for studies from 63 economies in Asia-Pacific. Papers or abstracts on cancer or general population's WTPQ were included, without limitation on publication language or year. Unit of analysis is an economy. WTPQ from the same economy for the same population (cancer versus general) and health vignette (life-threatening/cancer versus non-life threatening) was combined. GDP per capita and Consumer Price Index were obtained from international agencies. All values were adjusted to 2020 US dollars. RESULTS: 255 citations were screened. Nine studies from Australia, Japan, Korea, Taiwan, Thailand and Vietnam were identified, and four of them are directly about Ca-WTPQ. It ranges from $12335 in Vietnam to $28891 in Taiwan. For an economy, GDP per capita positively correlates with Ca-WTPQ (n=3 economies), and Gp-WTPQ for life-threatening/cancer diseases (n=5 economies). Due to small sample size, this is statistically insignificant. There is insufficient data on the economy level (n=1 only) to draw a difference between Ca-WTPQ, and Gp-WTPQ for life-threatening/cancer. If they are considered interchangeable, they are highly correlated with Gp-WTPQ for non-life-threatening disease (n=3). CONCLUSIONS: When Ca-WTPQ is unavailable within an economy, GDP per capita might facilitate the estimation. Gp-WTPQ for non-life-threatening diseases might inform the estimation of WTPQ for life-threatening/cancer disease, only under the strong assumption that cancer patients and the general population valuate cancer health improvement similarly.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB261
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Reimbursement & Access Policy, Thresholds & Opportunity Cost, Value Frameworks & Dossier Format
Disease
No Specific Disease, Oncology